Diagnostic Role of Platelet Lymphocyte Ratio(PLR) in Pancreatic Head Masses

Indian Journal of Surgery

Volumn 75, Issue 1, 2013, Pages 4-9

  Miglani, Ripan K ^a   Bhateja, Neeraj ^b   Bhat, Ravi Shanker ^b   Kumar, K V Ashok ^b  

^a Bengaluru Medical College and Research Institute   (India)

^b Department of Surgical Gastroenterology Bangalore Medical Civil Lines ^*  (India)

Author keywords

CA 19 9; Pancreatic head mass; Platelet lymphocyte ratio; PLR

Indexed keywords

EID: 84874573509     PISSN: 09722068     EISSN: 09739793     Source Type: Journal    
DOI: 10.1007/s12262-012-0443-6     Document Type: Article

References (12)

1. Goonnetilleke KS, Siriwardena AK (2007) Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 33: 266-270.
2. Bedi MM, Gandhi MD, Jacob G, Lekha V, Venugopal A, Ramesh H (2009) CA 19-9 to differentiate benign and malignant masses in chronic pancreatitis: is there any benefit? Indian J Gastroenterol 28: 24-27.
3. Smith RA, Bosonnet L, Ghaneh P, Sutton R (2008) The platelet-lymphocyte ratio improves the predictive value of serum CA19-9 levels in determining patient selection for staging laparoscopy in suspected periampullary cancer. Surgery 143: 658-666.
4. Salazar-Onfray F, Lopez MN, Mendoza-Naranjo A (2007) Paradoxical effects of cytokines in tumor immune surveillance and tumor escape. Cytokine Growth Factor Rev 18: 171-182.
5. Bellone G, Turletti A, Artusio E, Mareschi K, Carbone A, Tibaudi D, Robecchi A, Emanuelli G, Rodeck U (1999) Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol 155: 537-547.
6. Romano F, Uggeri F, Crippa S, Di Stefano G, Scotti M, Scaini A, Caprotti R, Uggeri F (2004) Immunodeficiency in different histotypes of radically operable gastrointestinal cancers. J Exp Clin Cancer Res 23: 195-200.
7. Fukunaga A, Miyamoto M, Cho Y, Murakami S, Kawarada Y et al (2004) CD8 tumor-infiltrating lymphocytes together with CD4 tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 28: 26-31.
8. Khorana AA, Fine RL (2004) Pancreatic cancer and thromboembolic disease. Lancet Oncol 5: 655-663.
9. Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F, Ghaneh P (2009) Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 197: 466-472.
10. Von Bernstorff W, Voss M, Freichel S, Schmid A, Vogel I, Jöhnk C, Henne-Bruns D, Kremer B, Kalthoff H (2001) Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res 7(Suppl): 925s-932s.
11. Alexandrakis MG, Passam FH, Moschandrea IA, Christophoridou AV, Pappa CA, Coulocheri SA, Kyriakou DS (2003) Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis. Am J Clin Oncol 26: 135-140.
12. Bhatti I, Peacock O, Lloyd G, Larvin M, Hall RI (2010) Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg 200: 197-203.